2. Signaling Pathways
  3. JAK/STAT Signaling
    Stem Cell/Wnt
  4. STAT

STAT

STAT

Related Products

PDF 1.6 MB

STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The transcription factors of this family are activated by Janus kinase and dysregulation of this pathway is frequently observed in primary tumours and leads to increased angiogenesis, enhanced survival of tumours and immunosuppression. Gene knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumour surveillance. STAT proteins were originally described as latent cytoplasmic transcription factors that require phosphorylation for nuclear retention. The unphosphorylated STAT proteins shuttle between cytosol and the nucleus waiting for its activation signal. Once the activated transcription factor reaches the nucleus, it binds to consensus DNA-recognition motif called gamma-activated sites (GAS) in the promoter region of cytokine-inducible genes and activates transcription of these genes.

STAT Isoform Specific Products:

STAT Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-159570
    XD2-149
    XD2-149 is a PROTAC targeting STAT3. XD2-149 consists of PROTAC target protein ligand Napabucasin (HY-13919) (red part), E3 ligase Thalidomide (HY-14658) (black part), and linker NH2-C5-Azacyclohexane-N-Boc (HY-159572) (blue part). The E3 ligase + linker conjugate is Thalidomide-NH-C5-azacyclohexane-N-Boc (HY-159571), and the active control of the target protein ligand is Thalidomide acid (HY-159573)[1].
    XD2-149
  • HY-169180
    AK-068-OH
    AK-068-OH (Compound 49) is an active control of ligand for target protein for PROTAC (HY-169179).
    AK-068-OH
  • HY-112447
    STAT3-IN-5
    		Inhibitor
    STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC50 value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer.
    STAT3-IN-5
  • HY-164445
    STAT3-IN-32
    		Inhibitor
    STAT3-IN-32 (compound 2p) is an orally active, potent STAT3 dual phosphorylation inhibitor with an indole-containing tetra-aromatic heterocycle scaffold. STAT3-IN-32 exhibits STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 5.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 4.2 nM. STAT3-IN-32 significantly blocks p-Tyr705 and p-Ser727 and causes the abrogation of the corresponding nuclear transcription and mitochondrial oxidative phosphorylation functions of STAT3 by targeting the STAT3 SH2 domain (KD=21.3 nM). STAT3-IN-32 exhibits significant suppressive effects in a pancreatic cancer xenograft model.
    STAT3-IN-32
  • HY-D145729F
    FAM-Danvatirsen
    		Inhibitor
    FAM-Danvatirsen is a FAM-labeled Danvatirsen (HY-145729). Danvatirsen is an antisense oligonucleotide targeting STAT3 that can be used in the study of cancer.
    FAM-Danvatirsen
  • HY-169242
    JAK1-IN-16
    		Inhibitor
    JAK1-IN-16 (compound 4l) is an inhibitor of JAK1/STAT3 and effectively downregulates TLR4 protein expression..
    JAK1-IN-16
  • HY-162405
    Smad2/3-IN-1
    		Inhibitor
    Smad2/3-IN-2 (Compound 27) is an inhibitor for TGF-β-dependent Smad2/3 and IL-4-dependent STAT6 signaling pathway, with IC50s of 90 and 20 nM, respectively.
    Smad2/3-IN-1
  • HY-163176
    WB518
    		Inhibitor
    WB518 is a potent STAT3 inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17.
    WB518
  • HY-168178
    Hsp110-STAT3 interaction-IN-2
    		Inhibitor
    Hsp110-STAT3 interaction-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 interaction-IN-2 can be used in pulmonary arterial hypertension (PAH) related research.
    Hsp110-STAT3 interaction-IN-2
  • HY-164349
    WZ-2-033
    		Inhibitor
    WZ-2-033 is a potent STAT3 inhibitor. WZ-2-033 inhibits MDA-MB-231, HCC70, and MDA-MB231-4175 cells proliferation, colony survival, migration, and invasion with IC50s of 0.7, 1.3, and 1.3 μM, respectively.
    WZ-2-033
  • HY-150251
    STAT3 degrader-2
    		Degrader
    STAT3 degrader-2 is a PROTAC-based degrader of STAT3. STAT3 degrader-2 can degrade the level of total STAT3 protein. STAT3 degrader-2 can be used for the research of cancer and other diseases. STAT3 degrader-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    STAT3 degrader-2
  • HY-162607
    STAT3-IN-28
    		Inhibitor
    STAT3-IN-28 (compound 18) is a STAT3 inhibitor. STAT3-IN-28 can inhibit the activation of microglia and has anti-neuroinflammatory effects. STAT3-IN-28 can cross the blood-brain barrier.
    STAT3-IN-28
  • HY-169361
    STAT3 ligand 5
    STAT3 ligand 5 is a ligand for STAT3, that can be used as target protein ligand for synthesis of PROTAC degrader SD-436 (HY-169360).
    STAT3 ligand 5
  • HY-119347R
    Cirsilineol (Standard)
    		Inhibitor
    Cirsilineol (Standard) is the analytical standard of Cirsilineol. This product is intended for research and analytical applications. Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.
    Cirsilineol (Standard)
  • HY-161136
    EGFR/STAT3-IN-1
    		Inhibitor
    EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC50 values for EGFR and STAT3 are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity.
    EGFR/STAT3-IN-1
  • HY-169007
    STAT3-IN-34
    		Inhibitor
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice.
    STAT3-IN-34
  • HY-P10201
    Ac-GpYLPQTV-NH2
    		Inhibitor
    Ac-GpYLPQTV-NH2 is a STAT3 inhibitor with an IC50 value of 0.33 μM. Ac-GpYLPQTV-NH2 has antitumor activity.
    Ac-GpYLPQTV-NH2
  • HY-159580
    STAT3-IN-31
    		Inhibitor
    STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1.
    STAT3-IN-31
  • HY-N0250R
    Saikosaponin D (Standard)
    		Inhibitor
    Saikosaponin D (Standard) is the analytical standard of Saikosaponin D. This product is intended for research and analytical applications. Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits selectin, STAT3 and NF-kB and activates estrogen receptor-β.
    Saikosaponin D (Standard)
  • HY-146666
    STAT3-IN-9
    		Inhibitor
    STAT3-IN-9 is a potent STAT3 inhibitor. STAT3-IN-9 inhibits the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). STAT3-IN-9 induces apoptosis and cell cycle arrest at the G2/M phase.
    STAT3-IN-9
Cat. No. Product Name / Synonyms Application Reactivity
STAT Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.